Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Baby Friendly Hospital Initiative

 
Introduction:
 
The Baby Friendly Hospital Initiative (BFHI) is a global accreditation program launched in 1991 by the World health organization (WHO) and United Nations International Children's Emergency Fund (UNICEF). 
In Lebanon, the BFHI is led by the Ministry of Public Health (MOPH), particularly the unit of Mother, Child and School health.
 
The BFHI is part of the National Infant and Young Child Feeding (IYCF) policy supported by UNICEF developed in March 2018.
 


The BFHI goal is to improve healthcare for babies, their mothers and families in Lebanon. The BFHI enables health care services to better support mothers and families to ensure that all newborns and infants get the best possible start in life.
 
 
Mission: 
 
The BFHI aims to protect, promote and support breastfeeding practices in healthcare facilities providing maternity and newborn services, while enabling timely and appropriate care and feeding of newborns who are not breastfed.
 
Objectives:

The Six main objectives of the BFHI are to:
  1. Enable mothers to make an informed choice about how to feed their newborns.
  2. Support early initiation of breastfeeding.
  3. Promote exclusive breastfeeding for the first 6 months of life, and introduce nutritionally-adequate and safe complementary (solid) foods at 6 months while continuing breastfeeding up to 2 years of age or beyond.
  4. End distribution of free and low-cost supplies of breast-milk substitutes to maternity wards and hospitals.
  5. Help reduce the levels of infant morbidity and mortality in Lebanon. 
  6. Increase the breastfeeding rates in Lebanon. 
Certification Process:
 
To become a designated Baby Friendly Hospital, hospitals must ensure compliance with the Lebanese law 47/2008 for “organizing the marketing of infant and young child feeding products and tools .
In addition, they should fulfill the requirements of the BFHI 10 steps that have been outlined by the WHO and UNICEF which were reviewed in 2018 and adapted by the Ministry of Public Health in Lebanon.
 
Appendix 1: Law 47/2008
Appendix 2: BFHI 10 steps

The baby friendly hospital (BFH) certification process includes several stages:

First stage:
 
  • Registration: 
The CEO of the hospital working towards baby friendly certification has to fill the BFHI registration form and send it to the unit of Mother, Child and School health at the MOPH via the following e-mail: motherchild@moph.gov.lb
 
Appendix 3: BFHI registration form
     
  • Self-appraisal process:

The hospital undergoes self-appraisal using the WHO self-appraisal tool
This tool is used to evaluate the hospital’s current application and practices of the ten steps to successful breastfeeding. This in turn will help in developing an action plan based on the results of the latter evaluation.
 
Appendix 4: WHO self-appraisal tool
 
  • Orientation visit:
Once the self-appraisal process is completed, an orientation visit to the candidate hospital is performed by the BFHI monitoring team to address the 10 steps criteria requiring additional work for the hospital to become baby friendly.
 
  • Application of commitment: 
The CEO of the hospital or an equivalent hospital staff will fill and sign an application of commitment if the candidate hospital has fulfilled the following requirements:
  • Forming a multidisciplinary breastfeeding committee
  • Assigning a breastfeeding coordinator.
  • Developing a breastfeeding policy that covers all the BFHI steps ( Hospital policy checklist and National Policy sample).
  • Developing the procedures needed for the BFHI 10 steps program.
  • Developing a BFHI work plan to ensure the implementation of 10 steps and the law 47/2008.
  • Developing a training plan for the clinical and non-clinical staff.
  • Developing a prenatal, perinatal and postnatal education plan.
  • Developing a data collection plan for documentation, auditing and evaluation of standards. 
All developed policies, plans and educational materials will be reviewed and approved by The BFHI monitoring team.
 
Appendix 5:  Application of commitment
Appendix 6: WHO policy checklist
Appendix 7: National Policy sample
 
Second stage:
 
  • Implementation stage: 
During this stage the hospital should:
  • Train the clinical staff providing clinical care for pregnant women, mothers and their babies, in addition to training the non-clinical staff providing non-clinical care for pregnant women, mothers and their babies or having contact with them in some aspect of their work.
  • Implement the hospital’s BFHI policy, action plans, and law 47/2008.
  • Collect pertinent data relevant to the 10 steps. Follow up evaluation visits and technical support will be provided by the BFHI monitoring team during the implementation phase.

Appendix 8: Baby Hospital Initiative Implementation Guidance -2018
 
 Third Stage:
 
  • Certification: 
Request for external assessment:
 
Once the evaluation report is completed by the BFHI monitoring team, the CEO of the hospital or an equivalent hospital staff should report to the MOPH (Mother, Child and School health unit) via the following email: motherchild@moph.gov.lb requesting an external assessment.

To note: The report of the national BFHI monitoring team should document the accomplishment of all steps and the hospital documentation and internal audits should be consistent with this report, to facilitate the external auditing process.
 
External assessment:
 
The external assessment is a two-step process:
  1. A verification of the hospital’s policies, educational material, action plans, staff training, and competency verification.
  2. On-site interviews with the staff and patients.
The assessment will be conducted by a certified BFHI assessor, assigned by the IYCF National Committee.
 
Upon successful completion of the required 10 steps by the candidate hospital as reported by the certified BFHI assessor, the hospital will be granted the BFHI certification for 5 years by the MOPH (Mother, Child and School health unit).
 
  • Recertification: 
A redesignation process requires the facility to follow the same steps
 
Appendixes:
Appendix 1: Law 4 /2008
Appendix 2: BFHI 10 steps
Appendix 3: BFHI registration form
Appendix 4: WHO self-appraisal tool
Appendix 5: Application of commitment
Appendix 6: WHO policy checklist
Appendix 7: National Policy sample
Appendix 8: Baby Hospital Initiative Implementation Guidance -2018
 
    ...
    8
    ...
ATC Name B/G Ingredients Dosage Form Price
J01FF01 DANALLI G Clindamycin HCl - 300mg 300mg Capsule 267,425 L.L
J02AC01 DIFLUCAN B Fluconazole - 50mg 50mg Capsule 622,199 L.L
J02AC01 DIFLUCAN B Fluconazole - 150mg 150mg Capsule 286,238 L.L
J05AR24 DELSTRIGO B Lamivudine - 300mg, Tenofovir disoproxil - 300mg, Doravirine - 100mg Tablet, film coated 48,879,793 L.L
J05AR27 DOLUTEGRAVIR/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE G Lamivudine - 300mg, Tenofovir disoproxil fumarate - 300mg, Dolutegravir - 50mg Tablet 54,836,160 L.L
J07CA11 DIPHTHERIA, TETANUS,PERTUSSIS, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE B Diphteria Toxoid1 - ?25Lf (?30IU)/0.5ml, Tetanus toxoid1 - ?2.5Lf (?40IU)/0.5ml, Bordetella pertussis (Whole cell) - ?16OU (?4.0IU)/0.5ml, HBs Antigen (r DNA)1 - ?10mcg/0.5ml, H. Influenza type b, purified capsular polysaccharide2 - 10mcg/0.5ml, 1 adsorbed on aluminium phosphate, Al+++ - ?1.25mg , 2 conjugated to tetanos toxoid carrier protein - Injectable suspension 1,515,854 L.L
L01AX04 DACARBAZINE MEDAC G Dacarbazine - 200mg 200mg Injectable powder for solution 15,866,076 L.L
L01AX04 DACARBAZINE MEDAC G Dacarbazine - 1,000mg 1,000mg Injectable powder for solution 5,411,654 L.L
L01BC06 DIROGIT G Capecitabine - 500mg 500mg Tablet, film coated 11,330,804 L.L
L01BC08 DACOGEN B Decitabine - 50mg 50mg Injectable lyophilised powder for solution 82,405,803 L.L
L01BC08 DACOGEN B Decitabine - 50mg 50mg Injectable lyophilised powder for solution 82,405,803 L.L
L01CD02 DOCETAXEL GP PHARM G Docetaxel - 40mg/ml 80mg/2ml Injectable concentrated solution+diluent 16,777,239 L.L
L01CD02 DOCETAXEL EBEWE G Docetaxel - 80mg/8ml 80mg/8ml Injectable solution 19,518,281 L.L
L01CD02 DOCETAXEL ACCORD G Docetaxel - 80mg/4ml 80mg/4ml Injectable concentrate for solution 15,099,641 L.L
L01CD02 DOCETAXEL SPC G Docetaxel - 80mg/4ml 80mg/4ml Injectable concentrate for solution 16,906,027 L.L
L01CD02 DOCETAXEL GP PHARM G Docetaxel - 40mg/ml 20mg/0.5ml Injectable concentrated solution+diluent 4,567,721 L.L
L01CD02 DOCETAXEL EBEWE G Docetaxel - 20mg/2ml 20mg/2ml Injectable solution 5,313,553 L.L
L01CD02 DOCETAXEL ACCORD G Docetaxel - 20mg/ml 20mg/1ml Injectable concentrate for solution 4,110,814 L.L
L01DB01 DOXORUBICINE EBEWE G Doxorubicin HCl - 10mg/5ml 10mg/5ml Injectable concentrated solution 428,686 L.L
L01DB01 DOXORUBICINE EBEWE G Doxorubicin HCl - 2mg/ml 50mg/25ml Injectable concentrated solution 1,804,780 L.L
L01DB01 DOXO-CELL G Doxorubicin HCl - 50mg/25ml 50mg/25ml Injectable solution 1,794,030 L.L
L01DB01 DOXORUBICINA TEDEC G Doxorubicin HCl - 50mg/25ml 50mg/25ml Injectable concentrate for solution 2,015,764 L.L
L01EA02 DASATINIB NEAPOLIS G Dasatinib - 70mg 70mg Tablet, film coated L.L
L01EA02 DASATINIB NEAPOLIS G Dasatinib - 50mg 50mg Tablet, film coated L.L
L01EA02 DASATINIB NEAPOLIS G Dasatinib - 70mg 70mg Tablet, film coated 127,364,905 L.L
L01EA02 DALEUBIN G Dasatinib - 70mg 70mg Tablet, film coated 93,260,179 L.L
L01EA02 DASATINIB NEAPOLIS G Dasatinib - 50mg 50mg Tablet, film coated 127,364,905 L.L
L01EA02 DALEUBIN G Dasatinib - 50mg 50mg Tablet, film coated 92,470,390 L.L
L01EA02 DASATINIB NEAPOLIS G Dasatinib - 20mg 20mg Tablet, film coated 103,165,573 L.L
L01EA02 DALEUBIN G Dasatinib - 20mg 20mg Tablet, film coated 75,022,315 L.L
    ...
    8
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025